This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cardwell K, Hughes CM, Ryan C. The association between anticholinergic medication burden and health related outcomes in the ‘oldest old’: a systematic review of the literature. Drugs Aging. 2015;32:835-48. 10.1007/s40266-015-0310-9.CardwellKHughesCMRyanC.The association between anticholinergic medication burden and health related outcomes in the ‘oldest old’: a systematic review of the literatureDrugs Aging2015328354810.1007/s40266-015-0310-926442862Open DOISearch in Google Scholar
Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neurophsychiatric side-effects in elderly patients. Neurol Sci. 2009;30:87-92. 10.1007/s10072-009-0033-y.CancelliIBeltrameMGigliGLValenteM.Drugs with anticholinergic properties: cognitive and neurophsychiatric side-effects in elderly patientsNeurol Sci.200930879210.1007/s10072-009-0033-y19229475Open DOISearch in Google Scholar
Fox C, Smith T, Maidment I, Chan W, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43: 604-15. 10.1093/ageing/afu096.FoxCSmithTMaidmentIChanWBuaNMyintPKEffect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic reviewAge Ageing2014436041510.1093/ageing/afu09625038833Open DOISearch in Google Scholar
Jamsen KM, Gnjidic D, Hilmer SN, Ilomäki J, Le Couteur DG, Blyth F, et al. Drug Burden Index and change in cognition over time in community-dwelling older men: the CHAMP study. Ann Med. 2017;49:157-64. 10.1080/07853890.2016.1252053.JamsenKMGnjidicDHilmerSNIlomäkiJLe CouteurDGBlythFDrug Burden Index and change in cognition over time in community-dwelling older men: the CHAMP studyAnn Med.2017491576410.1080/07853890.2016.125205327763767Open DOISearch in Google Scholar
Mayer T, Meid AD, Saum KU, Brenner H, Schöttker B, Seidlin HM, et al. Comparison of nine instruments to calculate anticholinergic load in a large cohort of older outpatients: association with cognitive and functional decline, falls and use of laxatives. Am J Geriatr Psychiatry. 2017;25:531-40. 10.1016/j.jagp.2017.01.009.MayerTMeidADSaumKUBrennerHSchöttkerBSeidlinHMComparison of nine instruments to calculate anticholinergic load in a large cohort of older outpatients: association with cognitive and functional decline, falls and use of laxativesAm J Geriatr Psychiatry2017255314010.1016/j.jagp.2017.01.00928233606Open DOISearch in Google Scholar
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:503-13. 10.1001/archinternmed.2007.106.RudolphJLSalowMJAngeliniMCMcGlincheyRE.The anticholinergic risk scale and anticholinergic adverse effects in older personsArch Intern Med.20081685031310.1001/archinternmed.2007.10618332297Open DOISearch in Google Scholar
Lönnroos E, Gnjidic D, Hilmer DN, Bell JS, Kautiainen H, Sulkava R, et al. Drug Burden Index and hospitalization among community-dwelling older people. Drugs Aging. 2012;29:395-404. 10.2165/11631420-000000000-00000.LönnroosEGnjidicDHilmerDNBellJSKautiainenHSulkavaRDrug Burden Index and hospitalization among community-dwelling older peopleDrugs Aging20122939540410.2165/11631420-000000000-0000022530705Open DOISearch in Google Scholar
Boccardi V, Baroni M, Paolacci L, Ercolani S, Longo A, Giordano M, et al. Anticholinergic burden and functional status in older people with cognitive impairment: results from the Regal project. J Nutr Health Aging. 2017;21:389-96. 10.1007/s12603-016-0787-x.BoccardiVBaroniMPaolacciLErcolaniSLongoAGiordanoMAnticholinergic burden and functional status in older people with cognitive impairment: results from the Regal projectJ Nutr Health Aging2017213899610.1007/s12603-016-0787-x28346565Open DOISearch in Google Scholar
Crispo JA, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, et al. Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One. 2016;11:e0150621. 10.1371/journal.pone.0150621.CrispoJAWillisAWThibaultDPFortinYHaysHDMcNairDSAssociations between anticholinergic burden and adverse health outcomes in Parkinson diseasePLoS One201611e015062110.1371/journal.pone.0150621477737526939130Open DOISearch in Google Scholar
Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481-6.CarnahanRMLundBCPerryPJPollockBGCulpKR.The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activityJ Clin Pharmacol.2006461481610.1177/009127000629212617101747Search in Google Scholar
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311-20. 10.2217/1745509X.4.3.311.BoustaniMCampbellNMungerSMaidmentIFoxC.Impact of anticholinergics on the aging brain: a review and practical applicationAging Health200843112010.2217/1745509X.4.3.311Open DOISearch in Google Scholar
Hilmer SN, Mager DE, Simonsick EM, Cao Y, Lung SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781-7.HilmerSNMagerDESimonsickEMCaoYLungSMWindhamBGA drug burden index to define the functional burden of medications in older peopleArch Intern Med.2007167781710.1001/archinte.167.8.78117452540Search in Google Scholar
Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13:17-24. 10.1111/j.1479-8301.2012.00418.x.LertxundiUDomingo-EchaburuSHernandezRPeralJMedranoJ.Expert-based drug lists to measure anticholinergic burden: similar names, different resultsPsychogeriatrics201313172410.1111/j.1479-8301.2012.00418.x23551407Open DOISearch in Google Scholar
Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63:85-90. 10.1111/jgs.13206.SalahudeenMSHilmerSNNishtalaPS.Comparison of anticholinergic risk scales and associations with adverse health outcomes in older peopleJ Am Geriatr Soc.201563859010.1111/jgs.1320625597560Open DOISearch in Google Scholar
Pont LG, Nielen JTH, McLachlan AJ, Gnjidic D, Chan L, Cumming RG, et al. Measuring anticholinergic drug exposure in older community dwelling Australian men: a comparison of four different measures. Br J Clin Pharmacol. 2015;80:1169-75. 10.1111/bcp.12670.PontLGNielenJTHMcLachlanAJGnjidicDChanLCummingRGMeasuring anticholinergic drug exposure in older community dwelling Australian men: a comparison of four different measuresBr J Clin Pharmacol.20158011697510.1111/bcp.12670463118925923961Open DOISearch in Google Scholar
Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69:1485-96. 10.1007/s00228-013-1499-3.DuránCEAzermaiMVander SticheleRH.Systematic review of anticholinergic risk scales in older adultsEur J Clin Pharmacol.20136914859610.1007/s00228-013-1499-323529548Open DOISearch in Google Scholar
Fleetcroft R, Cookson R, Steel N, Howe A. Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysis. Br J Gen Pract. 2011;61:e556-64. 10.3399/bjgp11X593839.FleetcroftRCooksonRSteelNHoweA.Correlation between prescribing quality and pharmaceutical costs in English primary care: national cross-sectional analysisBr J Gen Pract.201161e5566410.3399/bjgp11X593839316217822152735Open DOISearch in Google Scholar
Pavlič DR, Sever M, Klemenc-Ketiš Z, Švab I. Process quality indicators in family medicine: results of an international comparison. BMC Fam Pract. 2015;16:172. 10.1186/s12875-015-0386-7.PavličDRSeverMKlemenc-KetišZŠvabI.Process quality indicators in family medicine: results of an international comparisonBMC Fam Pract.20151617210.1186/s12875-015-0386-7466750026631138Open DOISearch in Google Scholar
Selic P, Cedilnik Gorup E, Gorup S, Petek Ster M, Rifel J, Klemenc Ketis Z. The effects of a web application and medical monitoring on the quality of medication, adverse drug events and adherence in the elderly living at home: a protocol of the study. Mater Sociomed. 2016;28:432-6. 10.5455/msm.2016.28.432-436.SelicPCedilnik GorupEGorupSPetek SterMRifelJKlemenc KetisZ.The effects of a web application and medical monitoring on the quality of medication, adverse drug events and adherence in the elderly living at home: a protocol of the studyMater Sociomed.201628432610.5455/msm.2016.28.432-436523965728144194Open DOISearch in Google Scholar
Tyrstrup M, van der Velden A, Engstrom S, Goderis G, Molstad S, Verheij T, et al. Antibiotic prescribing in relation to diagnoses and consultation rates in Belgium, the Netherlands and Sweden: use of European quality indicators. Scand J Prim Health Care. 2017;35: 10-8. 10.1080/02813432.2017.1288680.TyrstrupMvan der VeldenAEngstromSGoderisGMolstadSVerheijTAntibiotic prescribing in relation to diagnoses and consultation rates in Belgiumthe Netherlands and Swedenuse of European quality indicatorsScand J Prim Health Care20173510810.1080/02813432.2017.1288680536141328277045Open DOISearch in Google Scholar
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213-8. 10.1093/ageing/afu145.O’MahonyDO’SullivanDByrneSO’ConnorMNRyanCGallagherP.STOPP/START criteria for potentially inappropriate prescribing in older people: version 2Age Ageing201544213810.1093/ageing/afu145433972625324330Open DOISearch in Google Scholar
American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616-31. 10.1111/j.1532-5415.2012.03923.x.American Geriatrics Society 2012 Beers Criteria Update Expert PanelAmerican Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adultsJ Am Geriatr Soc.2012606163110.1111/j.1532-5415.2012.03923.x357167722376048Open DOISearch in Google Scholar
Selič P. Cross-sectional study exploring factors associated with depression in elderly living at home. In: Skela-Savič B, Hvalič Touzery S, editors. Continuous development of nursing in society and its contribution to health promotion: proceedings of lectures with peer review. Jesenice: Angela Boškin Faculty of Health Care, 2017:189-96.SeličP.Cross-sectional study exploring factors associated with depression in elderly living at homeSkela-SavičBHvalič TouzerySContinuous development of nursing in society and its contribution to health promotion: proceedings of lectures with peer reviewJeseniceAngela Boškin Faculty of Health Care201718996Search in Google Scholar
Klemenc-Ketis Z, Krizmaric M, Kersnik J. Age- and gender-specific prevalence of self-reported symptoms in adults. Cent Eur J Public Health. 2013;21:160-4.Klemenc-KetisZKrizmaricMKersnikJ.Age- and gender-specific prevalence of self-reported symptoms in adultsCent Eur J Public Health201321160410.21101/cejph.a382224344543Search in Google Scholar
Pivec N, Serdinšek T, Klemenc-Ketiš Z, Kersnik J. Prevalence of disease symptoms in Slovenian adult population and factors associated with their prevalence. Zdr Varst. 2014;53:262-9. 10.2478/sjph-2014-0028.PivecNSerdinšekTKlemenc-KetišZKersnikJ.Prevalence of disease symptoms in Slovenian adult population and factors associated with their prevalenceZdr Varst.201453262910.2478/sjph-2014-0028Open DOISearch in Google Scholar
Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2012;77:295-301. 10.1111/j.1365-2125.2012.04418.x.LaderM.Benzodiazepine harm: how can it be reduced?Br J Clin Pharmacol.20127729530110.1111/j.1365-2125.2012.04418.x401401522882333Open DOISearch in Google Scholar
Gjerden P, Bramness JG, Tvete IF, Slørdal L. The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015. Eur J Clin Pharmacol. 2017;73:1173-9. 10.1007/s00228-017-2281-8.GjerdenPBramnessJGTveteIFSlørdalL.The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015Eur J Clin Pharmacol.2017731173910.1007/s00228-017-2281-828623386Open DOISearch in Google Scholar
Anderson SL, VandeGriend JP. Quetiapine for insomnia: a review of the literature. Am J Health Syst Pharm. 2014;71:394-402. 10.2146/ajhp130221.AndersonSLVandeGriendJP.Quetiapine for insomnia: a review of the literatureAm J Health Syst Pharm.20147139440210.2146/ajhp13022124534594Open DOISearch in Google Scholar
Brett J. Concerns about quetiapine. Aust Prescr. 2015;38: 95-7.BrettJ.Concerns about quetiapineAust Prescr.20153895710.18773/austprescr.2015.032465396626648630Search in Google Scholar
Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, et al. Off-label use of atypical antipsychotics: an update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. Report No: 11-EHC087-EF.MaglioneMMaherARHuJWangZShanmanRShekellePGOff-label use of atypical antipsychotics: an update [Internet]Rockville (MD)Agency for Healthcare Research and Quality (US)2011Report No: 11-EHC087-EFSearch in Google Scholar
Štuhec M, Petrica D, Toni J. The cost and effects of atypical antipsychotic agents in patients with schizophrenia in Slovenia: a cost effectiveness study. Zdr Varst. 2013;52:27-38. 10.2478/sjph-2013-0004.ŠtuhecMPetricaDToniJ.The cost and effects of atypical antipsychotic agents in patients with schizophrenia in Slovenia: a cost effectiveness studyZdr Varst.201352273810.2478/sjph-2013-0004Open DOISearch in Google Scholar
Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease – a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006;60:15-22.HansenANBergheimRFagertunHLundHWiklundIMoumB.Long-term management of patients with symptoms of gastro-oesophageal reflux disease – a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners settingInt J Clin Pract.200660152210.1111/j.1368-5031.2006.00768.x16409423Search in Google Scholar
Aharony L, De Cock J, Nuotio MS, Pedone C, Rifel J, VandeWalle N, et al. Consensus document on the management of urinary incontinence in older people. Eur Geriatr Med. 2017;8:210-5. 10.1016/j.eurger.2017.04.002.AharonyLDe CockJNuotioMSPedoneCRifelJVandeWalleNConsensus document on the management of urinary incontinence in older peopleEur Geriatr Med.20178210510.1016/j.eurger.2017.04.002Open DOISearch in Google Scholar
Magin PJ, Morgan S, Tapley A, McCowan C, Parkinson L, Henderson KM, et al. Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical information. J Clin Pharm Ther. 2016;41:486-92. 10.1111/jcpt.12413.MaginPJMorganSTapleyAMcCowanCParkinsonLHendersonKMAnticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical informationJ Clin Pharm Ther.2016414869210.1111/jcpt.1241327349795Open DOISearch in Google Scholar
Central Drug Database of Slovenia. Accessed August 16th, 2017, at: http://www.cbz.si/cbz/bazazdr2.nsf/Search/$searchForm?SearchView.Central Drug Database of SloveniaAccessedAugust 16th2017athttp://www.cbz.si/cbz/bazazdr2.nsf/Search/$searchForm?SearchViewSearch in Google Scholar
Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28:25-35. 10.1007/s40520-015-0359-7.CollamatiAMartoneAMPosciaABrandiVCeliMMarzettiEAnticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidenceAging Clin Exp Res.201628253510.1007/s40520-015-0359-725930085Open DOISearch in Google Scholar
Lertxundi U, Isla A, Solinis MA, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, et al. Anticholinergic burden in Parkinson’s disease inpatients. Eur J Clin Pharmacol. 2015;71:1271-7. 10.1007/s00228-015-1919-7.LertxundiUIslaASolinisMADomingo-EchaburuSHernandezRPeral-AguirregoitiaJAnticholinergic burden in Parkinson’s disease inpatientsEur J Clin Pharmacol.2015711271710.1007/s00228-015-1919-726254777Open DOISearch in Google Scholar
